Clinical Application of 89Zr-s-C1 PET/CT Imaging in Solid Tumors
Recruiting now
Conditions studied: Solid Tumors
In brief
This project is driven by clinical needs and focuses on the mucin (MUC) family, key glycopeptide antigens involved in mediating immune evasion in solid tumors. We selected multiple members of this family as research subjects. Based on the MUC18 target, we developed the probe ⁸⁹Zr-SS-CNB001 (HuAA98-14, hereafter referred to as ⁸⁹Zr-s-C1). Studies have demonstrated that ⁸⁹Zr-s-C1 PET/CT enables noninvasive in vivo identification of tumor lesions in patients with solid tumors, and its imaging efficacy positively correlates with MUC18 expression levels in the patient's tumor tissue.
Key facts
- Study ID
- NCT07529002
- Run by
- Peking University Cancer Hospital & Institute
- People needed
- 20
- Starts
- 2026-04-14
- Expected to finish
- 2028-03-01
- Last updated by the study team
- 2026-04-14
Who can join
Age: 15 and older, up to 70. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Beijing cancer hosipitaal — Beijing, Beijing Municipality, China (enrolling)
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.